Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simon's two-stage trial
BMJ Open. 2023 Apr 11;13(4):e064809. doi: 10.1136/bmjopen-2022-064809.ABSTRACTINTRODUCTION: Curative intent treatment of head and neck cancer (HNC) is frequently radiation therapy over 7 weeks with concurrent chemotherapy. This regimen is effective but carries a burden of toxicity leading to severe pain and treatment breaks portending inferior outcomes. Conventional palliation methods include opioids, anticonvulsants and local anaesthetics. Breakthrough toxicities are nevertheless ubiquitous and present an urgent unmet need. Ketamine is an inexpensive drug with mechanisms of analgesia outside the opioid pathway including N...
Source: Cancer Control - April 11, 2023 Category: Cancer & Oncology Authors: Daniel Koffler Jacob Eckstein Joseph Herman Diana Martins-Welch Nagashree Seetharamu Maged Ghaly Nina Kohn Louis Potters Douglas Frank Kevin Sullivan Bhupesh Parashar Source Type: research
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Conclusion: MK-8353/selumetinib 50/25 mg and 100/50 mg had acceptable safety and tolerability, whereas 150/75 mg was not tolerable. No responses were observed. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 11, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simons two-stage trial
Introduction
Curative intent treatment of head and neck cancer (HNC) is frequently radiation therapy over 7 weeks with concurrent chemotherapy. This regimen is effective but carries a burden of toxicity leading to severe pain and treatment breaks portending inferior outcomes. Conventional palliation methods include opioids, anticonvulsants and local anaesthetics. Breakthrough toxicities are nevertheless ubiquitous and present an urgent unmet need. Ketamine is an inexpensive drug with mechanisms of analgesia outside the opioid pathway including N-methyl-D-aspartate (NMDA) receptor antagonism and a pharmacologically unique p...
Source: BMJ Open - April 11, 2023 Category: General Medicine Authors: Koffler, D., Eckstein, J., Herman, J., Martins-Welch, D., Seetharamu, N., Ghaly, M., Kohn, N., Potters, L., Frank, D., Sullivan, K., Parashar, B. Tags: Open access, Oncology Source Type: research
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
(Source: Investigational New Drugs)
Source: Investigational New Drugs - April 10, 2023 Category: Drugs & Pharmacology Source Type: research
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
AbstractB7 homolog 3 protein (B7-H3), an immune checkpoint molecule belonging to the B7 family, has been studied as a target for the development of anti-cancer treatment; however, changes in B7-H3 expression during the clinical course remain unknown. This retrospective study aimed to investigate changes in B7-H3 expression of lung cancer specimens in patients with advanced lung cancer following various anti-cancer treatments. The immunohistochemistry (IHC) score was evaluated on a 0 –3 scale, and B7-H3 expression was considered positive for grade ≥ 2. The difference in IHC scores before and after anti-cancer treatm...
Source: Investigational New Drugs - April 10, 2023 Category: Drugs & Pharmacology Source Type: research
Iruplinalkib (WX ‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
In conclusion, iruplinalkib, a highly active and selective ALK/ROS1 inhibitor, exhibited strong antitumor effects in vitro and in crizotinib-resistant models. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 10, 2023 Category: Drugs & Pharmacology Source Type: research
Mesenchymal stem cells: a trojan horse to treat glioblastoma
SummaryGlioblastoma multiforme (GBM) is the most common and lethal primary tumor of the central nervous system. What makes it so dreadful is the very low survival rate, despite the existence of a standard treatment plan. An innovative and more effective way to treat glioblastoma based on Mesenchymal Stem Cells (MSCs) has been explored recently. MSCs are a group of endogenous multipotent stem cells that could mainly be harvested from adipose tissue, bone marrow, and umbilical cord. Having the ability to migrate toward the tumor using multiple types of binding receptors, they could be used either as a direct treatment (wheth...
Source: Investigational New Drugs - April 5, 2023 Category: Drugs & Pharmacology Source Type: research
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory s ézary syndrome
We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monothera py. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2023 Category: Drugs & Pharmacology Source Type: research
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer
AbstractThe usage of monoclonal antibodies (mAbs) and antibody fragments, as a matter associated with the biopharmaceutical industry, is increasingly growing. Harmonious with this concept, we designed an exclusive modeled single-chain variable fragment (scFv) against mesenchymal-epithelial transition (MET) oncoprotein. This scFv was newly developed from Onartuzumab sequence by gene cloning, and expression using bacterial host. Herein, we examined its preclinical efficacy for the reduction of tumor growth, invasiveness and angiogenesis in vitro and in vivo. Expressed anti-MET scFv demonstrated high binding capacity (48.8%) ...
Source: Investigational New Drugs - April 1, 2023 Category: Drugs & Pharmacology Source Type: research
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
This study aimed to describe the real-world efficacy and safety of the combination therapy of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC). This retrospective analysis of a multicenter registry cohort included 268 patients treated with Atezo/Bev. The incidence of adverse events (AE) and its impact on overall survival (OS) and progression-free survival (PFS) were analyzed. Of the 268 patients, 230 (85.8%) experienced AE. The median OS and PFS in the whole cohort were 462 and 239 days, respectively. The OS and PFS were not different in terms of AE, but they were significantly short...
Source: Investigational New Drugs - March 30, 2023 Category: Drugs & Pharmacology Source Type: research
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
In this study, we interrupted GM-CSF expression in CAR-T cells by inserting the GM-CSF shRNA-expression cassette in the CAR vector. Reduction of GM-CSF in CAR-T cells could decrease the level of several proinflammatory cytokines without hampering the killing capacity. The manufacture of GM-CSF knockdown CAR-T cells does not require complicated transfections, which makes it more practical and feasible for clinical application. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis
Conclusion: MG is a serious and rare adverse reaction to nivolumab. Nivolumab-induced MG should be timely and correctly identified, and immunotherapy should be given. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
Investigational new drugs for the treatment of Dravet Syndrome: an update
Expert Opin Investig Drugs. 2023 Mar 18. doi: 10.1080/13543784.2023.2193680. Online ahead of print.ABSTRACTINTRODUCTION: While there are already approved anticonvulsants for treatment of children with Dravet syndrome, disease modifying therapy is on its beginning.AREAS COVERED: : This narrative review is updating the latest information about efficacy and safety of both anticonvulsant and disease modifying investigational drugs for Dravet syndrome. Relevant publications were searched for in MEDLINE, GOOGLE SCHOLAR, SCINDEKS and CLINICALTRIALS.GOV databases, from the dates of their foundation till January 2023.EXPERT OPINION...
Source: Expert Opinion on Investigational Drugs - March 18, 2023 Category: Drugs & Pharmacology Authors: Slobodan M Jankovi ć Sne žana V Janković Radi ša Vojinović Sne žana Lukić Source Type: research
